WRF
ADMS

Waddell & Reed Financial’s Adamas Pharmaceuticals ADMS Stock Holding History

Waddell & Reed Financial’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-50,200
Closed -$1.3M – 583
2018
Q2 		$1.3M Hold
50,200
– – ﹤0.01% 525
2018
Q1 		$1.2M Buy
+50,200
New +$1.58M ﹤0.01% 511

Other funds holding ADMS

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BWCA
Brenner West Capital Advisors New York $804M AUM 16.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Waddell & Reed Financial's ADMS Position: Q3 2018 in Review

Waddell & Reed Financial sold out of Adamas Pharmaceuticals (ADMS) in Q3 2018, closing a stake of 50,200 shares — an estimated $1.3M sold.

Waddell & Reed Financial first reported a position in ADMS in Q1 2018 and held it in 2 quarters. The position peaked at $1.3M in Q2 2018. 125 funds tracked by Wall St. Rank hold ADMS as of Q3 2018.

  • Waddell & Reed Financial reported no remaining Adamas Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Waddell & Reed Financial sold 50,200 Adamas Pharmaceuticals shares in Q3 2018, an estimated $1.3M.
  • Waddell & Reed Financial first reported a position in Adamas Pharmaceuticals in Q1 2018 and held it in 2 quarters.
  • Waddell & Reed Financial's Adamas Pharmaceuticals position peaked at $1.3M in Q2 2018.
  • 125 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q3 2018.

Based on Waddell & Reed Financial's 13F filing for Q3 2018, filed 14 Nov 2018.